An engineered monomer binding-protein for α-synuclein efficiently inhibits the proliferation of amyloid fibrils

  1. Emil Dandanell Agerschou
  2. Patrick Flagmeier
  3. Theodora Saridaki
  4. Céline Galvagnion
  5. Daniel Komnig
  6. Laetitia Heid
  7. Vibha Prasad
  8. Hamed Shaykhalishahi
  9. Dieter Willbold
  10. Christopher M Dobson
  11. Aaron Voigt
  12. Björn Falkenbürger  Is a corresponding author
  13. Wolfgang Hoyer  Is a corresponding author
  14. Alexander K Buell  Is a corresponding author
  1. Heinrich Heine University Düsseldorf, Germany
  2. University of Cambridge, United Kingdom
  3. RWTH Aachen University, Germany
  4. Technical University of Denmark, Denmark

Abstract

Removing or preventing the formation of α-synuclein aggregates is a plausible strategy against Parkinson's disease. To this end we have engineered the β-wrapin AS69 to bind monomeric α-synuclein with high affinity. In cultured cells, AS69 reduced the self-interaction of α-synuclein and the formation of visible α-synuclein aggregates. In flies, AS69 reduced α-synuclein aggregates and the locomotor deficit resulting from α-synuclein expression in neuronal cells. In biophysical experiments in vitro, AS69 highly sub-stoichiometrically inhibited both primary and autocatalytic secondary nucleation processes, even in the presence of a large excess of monomer. We present evidence that the AS69-α-synuclein complex, rather than the free AS69, is the inhibitory species responsible for sub-stoichiometric inhibition of secondary nucleation. These results represent a new paradigm that high affinity monomer binders can lead to strongly sub-stoichiometric inhibition of nucleation processes.

Data availability

- Numerical data represented in the graphs for cell culture and fly experiments will be made publicly available on osf.io as we did for previous publications.- The numerical data for the biophysical experiments will be made publicly available within the same repository on osf.io.- The raw images of the gels used in the publication will be made publicly available.All data have been deposited on osf.io ( https://osf.io/6n2gs/?view_only=7eb7024d8ecb460a817cd0ed35978339 ) and will be made available in the event of publication

The following data sets were generated

Article and author information

Author details

  1. Emil Dandanell Agerschou

    Institute of Physical Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Patrick Flagmeier

    Department of Chemistry, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1204-5340
  3. Theodora Saridaki

    Department of Neurology, RWTH Aachen University, Aachen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Céline Galvagnion

    Institute of Physical Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Daniel Komnig

    Department of Neurology, RWTH Aachen University, Aachen, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6312-5236
  6. Laetitia Heid

    Institute of Physical Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Vibha Prasad

    Department of Neurology, RWTH Aachen University, Aachen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Hamed Shaykhalishahi

    Institute of Physical Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Dieter Willbold

    Institute of Physical Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0065-7366
  10. Christopher M Dobson

    Department of Chemistry, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Aaron Voigt

    Department of Neurology, RWTH Aachen University, Aachen, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0428-7462
  12. Björn Falkenbürger

    Department of Neurology, RWTH Aachen University, Aachen, Germany
    For correspondence
    bfalkenburger@ukaachen.de
    Competing interests
    The authors declare that no competing interests exist.
  13. Wolfgang Hoyer

    Institute of Physical Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    For correspondence
    wolfgang.hoyer@hhu.de
    Competing interests
    The authors declare that no competing interests exist.
  14. Alexander K Buell

    Biotechnology and Biomedicine, Technical University of Denmark, Kgs Lyngby, Denmark
    For correspondence
    alebu@dtu.dk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1161-3622

Funding

Leverhulme Trust

  • Alexander K Buell

Boehringer Ingelheim Fonds

  • Patrick Flagmeier

Studienstiftung des Deutschen Volkes

  • Patrick Flagmeier

Alexander von Humboldt-Stiftung

  • Céline Galvagnion

H2020 European Research Council (726368)

  • Céline Galvagnion

Parkinson's and Movement Disorder Foundation

  • Alexander K Buell

European Commission (706551)

  • Céline Galvagnion

Novo Nordisk Foundation

  • Alexander K Buell

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Andrew B West, Duke University, United States

Version history

  1. Received: February 25, 2019
  2. Accepted: August 4, 2019
  3. Accepted Manuscript published: August 7, 2019 (version 1)
  4. Accepted Manuscript updated: August 21, 2019 (version 2)
  5. Version of Record published: September 3, 2019 (version 3)
  6. Version of Record updated: December 11, 2019 (version 4)

Copyright

© 2019, Agerschou et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,278
    views
  • 830
    downloads
  • 48
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Emil Dandanell Agerschou
  2. Patrick Flagmeier
  3. Theodora Saridaki
  4. Céline Galvagnion
  5. Daniel Komnig
  6. Laetitia Heid
  7. Vibha Prasad
  8. Hamed Shaykhalishahi
  9. Dieter Willbold
  10. Christopher M Dobson
  11. Aaron Voigt
  12. Björn Falkenbürger
  13. Wolfgang Hoyer
  14. Alexander K Buell
(2019)
An engineered monomer binding-protein for α-synuclein efficiently inhibits the proliferation of amyloid fibrils
eLife 8:e46112.
https://doi.org/10.7554/eLife.46112

Share this article

https://doi.org/10.7554/eLife.46112

Further reading

    1. Genetics and Genomics
    2. Neuroscience
    Kenneth Chiou, Noah Snyder-Mackler
    Insight

    Single-cell RNA sequencing reveals the extent to which marmosets carry genetically distinct cells from their siblings.

    1. Neuroscience
    Flavio J Schmidig, Simon Ruch, Katharina Henke
    Research Article

    We are unresponsive during slow-wave sleep but continue monitoring external events for survival. Our brain wakens us when danger is imminent. If events are non-threatening, our brain might store them for later consideration to improve decision-making. To test this hypothesis, we examined whether novel vocabulary consisting of simultaneously played pseudowords and translation words are encoded/stored during sleep, and which neural-electrical events facilitate encoding/storage. An algorithm for brain-state-dependent stimulation selectively targeted word pairs to slow-wave peaks or troughs. Retrieval tests were given 12 and 36 hr later. These tests required decisions regarding the semantic category of previously sleep-played pseudowords. The sleep-played vocabulary influenced awake decision-making 36 hr later, if targeted to troughs. The words’ linguistic processing raised neural complexity. The words’ semantic-associative encoding was supported by increased theta power during the ensuing peak. Fast-spindle power ramped up during a second peak likely aiding consolidation. Hence, new vocabulary played during slow-wave sleep was stored and influenced decision-making days later.